TY - JOUR
T1 - Phenotypes of disease severity in a cohort of hospitalized COVID-19 patients
T2 - Results from the IMPACC study
AU - the IMPACC study group members
AU - Ozonoff, Al
AU - Schaenman, Joanna
AU - Jayavelu, Naresh Doni
AU - Milliren, Carly E.
AU - Calfee, Carolyn S.
AU - Cairns, Charles B.
AU - Kraft, Monica
AU - Baden, Lindsey R.
AU - Shaw, Albert C.
AU - Krammer, Florian
AU - van Bakel, Harm
AU - Esserman, Denise A.
AU - Liu, Shanshan
AU - Sesma, Ana Fernandez
AU - Simon, Viviana
AU - Hafler, David A.
AU - Montgomery, Ruth R.
AU - Kleinstein, Steven H.
AU - Levy, Ofer
AU - Bime, Christian
AU - Haddad, Elias K.
AU - Erle, David J.
AU - Pulendran, Bali
AU - Nadeau, Kari C.
AU - Davis, Mark M.
AU - Hough, Catherine L.
AU - Messer, William B.
AU - Higuita, Nelson I.Agudelo
AU - Metcalf, Jordan P.
AU - Atkinson, Mark A.
AU - Brakenridge, Scott C.
AU - Corry, David
AU - Kheradmand, Farrah
AU - Ehrlich, Lauren I.R.
AU - Melamed, Esther
AU - McComsey, Grace A.
AU - Sekaly, Rafick
AU - Diray-Arce, Joann
AU - Peters, Bjoern
AU - Augustine, Alison D.
AU - Reed, Elaine F.
AU - Altman, Matthew C.
AU - Rahman, Adeeb
AU - Stadlbauer, Daniel
AU - Kim-Schulze, Seunghee
AU - Gonzalez-Reiche, Ana Silvia
AU - Saksena, Miti
AU - Altman, Deena
AU - Kojic, Erna
AU - Mulder, Lubbertus CF
N1 - Funding Information:
C.B.C reports funds paid to institution from the National Institute of Health - National Institute of Allergy and Infectious Diseases for the completion of this manuscript. C.B.C also reports a grant paid to institution by the Bill & Melinda Gates Foundation for Covid-19 work. C.B.C is a consultant for bioMerieux on clinical biomarkers. He reports his participation on a data safety monitoring board or advisory board for the Convalescent plasma Covid-19 study for the National Heart, Lung and Blood Institute (NHLBI). CBC is also President, Board of Directors for the National Foundation of Emergency Medicine (NFEM), a non-profit supporting emergency medicine research and researchers.
Funding Information:
The study was funded by the United States National Institutes of Health through the following grants: 5R01AI135803-03 , 5U19AI118608-04 , 5U19 AI128910-04 , 4U19AI090023-11 , 4U19AI118610-06 , R01AI145835-01A1S1 , 5U19AI062629-17 , 5U19AI057229-17 , 5U19AI125357-05 , 5U19AI128913-03 , 3U19AI077439-13 , 5U54AI142766-03 , 5R01AI104870-07 , 3U19AI089992-09 , 3U19AI128913-03 .
Funding Information:
M.A.A reports a grant from the National Institute of Health - National Institute of Allergy and Infectious Diseases for the completion of this manuscript (5U54AI142766-03).
Funding Information:
R.M reports a grant from the National Institute of Health for the completion of this manuscript (AI 089992). R. M served as a Counselor for the Society of Leukocyte Biology from 2018 to 2021.
Funding Information:
W.M reports a grant from the National Institute of Health – National Institute of Allergy and Infectious Diseases for the completion of this manuscript (NIH NIAID R01AI14583).
Funding Information:
L.E reports grant awarded to institution from the National Institute of Health (NIH R01AI104870-S1).
Funding Information:
J.P.M reports funds paid to institution for grants or contracts from the National Institute of Health for the completion of this manuscript (NIH Grant # 3U19AI062629-17S2).
Funding Information:
C.L.H reports a grant awarded to institution by the National Institute of Health and the American Lung Association. C.L.H also reports having received consulting fees from the National Institute of Health. C.L.H has received payment for medical grand rounds at institution and support for attending meetings and/or travel from Critical care trialists, critical care reviews and multiple universities. C.L.H is on the data safety monitoring board of QuantumHealth for iSPY COVID and is on the board of directors for the American Thoracic Society.
Funding Information:
F.KR has received funds from the National Institute of Allergy and Infectious Diseases Collaborative Influenza Vaccine Innovation Centers (CIVIC) contract 75N93019C00051, the National Institute of Health - Centers of Excellence for influenza Research and Response, (CEIRR), 75N93021C00014, the JPB Foundation and the Open Philanthropy Project (research grant 2020-215611, 5384), the National Cancer Institute, National Institutes of Health, under Contract No. 75N91019D00024, Task Order No. 75N91020F00003 and Research funding from Pfizer for development of animal models for SARS-CoV-2. F.KR receives royalties from Avimex, and receives consulting fees from Pfizer, Seqirus, Avimex and Third Rock Ventures. F.KR has received several payments or honoraria for academic lectures over the past two years. F. KR is listed as a co-inventor on patents filed for applications relating to SARS-CoV-2 serological assays (the “Serology Assays”) and NDV-based SARS-CoV-2 vaccines.
Publisher Copyright:
© 2022 The Authors
PY - 2022/9
Y1 - 2022/9
N2 - Background: Better understanding of the association between characteristics of patients hospitalized with coronavirus disease 2019 (COVID-19) and outcome is needed to further improve upon patient management. Methods: Immunophenotyping Assessment in a COVID-19 Cohort (IMPACC) is a prospective, observational study of 1164 patients from 20 hospitals across the United States. Disease severity was assessed using a 7-point ordinal scale based on degree of respiratory illness. Patients were prospectively surveyed for 1 year after discharge for post-acute sequalae of COVID-19 (PASC) through quarterly surveys. Demographics, comorbidities, radiographic findings, clinical laboratory values, SARS-CoV-2 PCR and serology were captured over a 28-day period. Multivariable logistic regression was performed. Findings: The median age was 59 years (interquartile range [IQR] 20); 711 (61%) were men; overall mortality was 14%, and 228 (20%) required invasive mechanical ventilation. Unsupervised clustering of ordinal score over time revealed distinct disease course trajectories. Risk factors associated with prolonged hospitalization or death by day 28 included age ≥ 65 years (odds ratio [OR], 2.01; 95% CI 1.28–3.17), Hispanic ethnicity (OR, 1.71; 95% CI 1.13–2.57), elevated baseline creatinine (OR 2.80; 95% CI 1.63– 4.80) or troponin (OR 1.89; 95% 1.03–3.47), baseline lymphopenia (OR 2.19; 95% CI 1.61–2.97), presence of infiltrate by chest imaging (OR 3.16; 95% CI 1.96–5.10), and high SARS-CoV2 viral load (OR 1.53; 95% CI 1.17–2.00). Fatal cases had the lowest ratio of SARS-CoV-2 antibody to viral load levels compared to other trajectories over time (p=0.001). 589 survivors (51%) completed at least one survey at follow-up with 305 (52%) having at least one symptom consistent with PASC, most commonly dyspnea (56% among symptomatic patients). Female sex was the only associated risk factor for PASC. Interpretation: Integration of PCR cycle threshold, and antibody values with demographics, comorbidities, and laboratory/radiographic findings identified risk factors for 28-day outcome severity, though only female sex was associated with PASC. Longitudinal clinical phenotyping offers important insights, and provides a framework for immunophenotyping for acute and long COVID-19. Funding: NIH.
AB - Background: Better understanding of the association between characteristics of patients hospitalized with coronavirus disease 2019 (COVID-19) and outcome is needed to further improve upon patient management. Methods: Immunophenotyping Assessment in a COVID-19 Cohort (IMPACC) is a prospective, observational study of 1164 patients from 20 hospitals across the United States. Disease severity was assessed using a 7-point ordinal scale based on degree of respiratory illness. Patients were prospectively surveyed for 1 year after discharge for post-acute sequalae of COVID-19 (PASC) through quarterly surveys. Demographics, comorbidities, radiographic findings, clinical laboratory values, SARS-CoV-2 PCR and serology were captured over a 28-day period. Multivariable logistic regression was performed. Findings: The median age was 59 years (interquartile range [IQR] 20); 711 (61%) were men; overall mortality was 14%, and 228 (20%) required invasive mechanical ventilation. Unsupervised clustering of ordinal score over time revealed distinct disease course trajectories. Risk factors associated with prolonged hospitalization or death by day 28 included age ≥ 65 years (odds ratio [OR], 2.01; 95% CI 1.28–3.17), Hispanic ethnicity (OR, 1.71; 95% CI 1.13–2.57), elevated baseline creatinine (OR 2.80; 95% CI 1.63– 4.80) or troponin (OR 1.89; 95% 1.03–3.47), baseline lymphopenia (OR 2.19; 95% CI 1.61–2.97), presence of infiltrate by chest imaging (OR 3.16; 95% CI 1.96–5.10), and high SARS-CoV2 viral load (OR 1.53; 95% CI 1.17–2.00). Fatal cases had the lowest ratio of SARS-CoV-2 antibody to viral load levels compared to other trajectories over time (p=0.001). 589 survivors (51%) completed at least one survey at follow-up with 305 (52%) having at least one symptom consistent with PASC, most commonly dyspnea (56% among symptomatic patients). Female sex was the only associated risk factor for PASC. Interpretation: Integration of PCR cycle threshold, and antibody values with demographics, comorbidities, and laboratory/radiographic findings identified risk factors for 28-day outcome severity, though only female sex was associated with PASC. Longitudinal clinical phenotyping offers important insights, and provides a framework for immunophenotyping for acute and long COVID-19. Funding: NIH.
KW - Antibody
KW - COVID-19
KW - SARS-CoV-2
KW - Viral load
UR - http://www.scopus.com/inward/record.url?scp=85135716647&partnerID=8YFLogxK
U2 - 10.1016/j.ebiom.2022.104208
DO - 10.1016/j.ebiom.2022.104208
M3 - Article
AN - SCOPUS:85135716647
SN - 2352-3964
VL - 83
JO - eBioMedicine
JF - eBioMedicine
M1 - 104208
ER -